Exelixis (Nasdaq:EXEL) - Aandelenkoers, Nieuws & Analyse

EXEL Overzicht aandelen

Exelixis, Inc., een oncologiebedrijf, richt zich op het ontdekken, ontwikkelen en commercialiseren van nieuwe medicijnen voor moeilijk te behandelen kankers in de Verenigde Staten.

Over het bedrijf

EXEL fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	2/6
Prestaties in het verleden	5/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 70.6% onder onze schatting van de reële waarde

De winst zal naar verwachting met 15.61% per jaar groeien

De winst groeide het afgelopen jaar met 407.1%

Risicoanalyse

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Dynamic Collaborations And Innovation Propel Growth In Oncology Breakthroughs

Key Takeaways Strategic collaborations and pipeline advancements, including Zanza and cabo, are expected to drive significant revenue growth and stabilize future earnings. Sustained R&D investments and spending prioritization aim to support future pipeline developments, enhance net margins, and increase shareholder returns.

View narrative

US$30.15

13.7% overvalued

6.56%

Revenue growth p.a.

5 days ago

Exelixis, Inc. Concurrenten

BioMarin Pharmaceutical

NasdaqGS:BMRN

US$12.7b

Neurocrine Biosciences

NasdaqGS:NBIX

US$12.4b

Halozyme Therapeutics

NasdaqGS:HALO

US$7.3b

United Therapeutics

NasdaqGS:UTHR

US$16.7b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Exelixis
Historische aandelenkoersen
Huidige aandelenkoers	US$34.29
52 Week Hoogtepunt	US$34.65
52 Week Laag	US$19.20
Bèta	0.54
11 maand verandering	28.62%
3 maanden verandering	46.23%
1 Jaar Verandering	64.54%
33 jaar verandering	82.78%
5 jaar verandering	120.51%
Verandering sinds IPO	125.78%

Recent nieuws en updates

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Oct 31

Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Oct 31

Recent updates

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Oct 31

Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Oct 31

If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

Jun 14

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

May 24

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

May 07

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

May 02

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Apr 22

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Mar 28

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Feb 26

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Jan 17

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Dec 27

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

May 30

Rendement voor aandeelhouders

	EXEL	US Biotechs	US Markt
7D	20.3%	-1.4%	-1.9%
1Y	64.5%	20.2%	30.4%

Rendement versus industrie: EXEL overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 20.2 % opleverde.

Rendement versus markt: EXEL overtrof de US markt, die het afgelopen jaar een rendement opleverde van 30.4 %.

Prijsvolatiliteit

Is EXEL's price volatile compared to industry and market?
EXEL volatility
EXEL Average Weekly Movement	6.4%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: EXEL heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van EXEL is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1994	1,310	Mike Morrissey	www.exelixis.com

Exelixis, Inc., een oncologiebedrijf, richt zich op het ontdekken, ontwikkelen en op de markt brengen van nieuwe geneesmiddelen voor moeilijk te behandelen kankers in de Verenigde Staten. Het bedrijf biedt CABOMETYX-tabletten aan voor de behandeling van patiënten met gevorderd niercelcarcinoom die een voorafgaande anti-angiogene therapie hebben ondergaan, en COMETRIQ-capsules voor de behandeling van progressieve en metastatische medullaire schildklierkanker. CABOMETYX en COMETRIQ zijn afgeleid van cabozantinib, een remmer van meerdere tyrosinekinasen, waaronder MET-, AXL-, RET- en VEGF-receptoren.

Exelixis, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Exelixis zich tot de beurswaarde?
EXEL fundamentele statistieken
Marktkapitalisatie	US$9.74b
Inkomsten(TTM)	US$466.92m
Inkomsten(TTM)	US$2.08b

21.0x

Koers/Winstverhouding

4.7x

P/S-verhouding

Is EXEL overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
EXEL resultatenrekening (TTM)
Inkomsten	US$2.08b
Kosten van inkomsten	US$78.00m
Brutowinst	US$2.00b
Overige uitgaven	US$1.54b
Inkomsten	US$466.92m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	1.64
Brutomarge	96.25%
Nettowinstmarge	22.43%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde EXEL op de lange termijn?

Bekijk historische prestaties en vergelijking

EXEL Overzicht aandelen

Beloningen

Risicoanalyse

Dynamic Collaborations And Innovation Propel Growth In Oncology Breakthroughs

Exelixis, Inc. Concurrenten

NasdaqGS:BMRN

US$12.7b

NasdaqGS:NBIX

US$12.4b

NasdaqGS:HALO

US$7.3b

NasdaqGS:UTHR

US$16.7b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Investor sentiment improves as stock rises 20%

Independent Director notifies of intention to sell stock

Price target increased by 7.1% to US$31.60

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Investor sentiment improves as stock rises 20%

Independent Director notifies of intention to sell stock

Price target increased by 7.1% to US$31.60

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2024

Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching

Exelixis, Inc. to Report Q3, 2024 Results on Oct 29, 2024

CEO, President & Director exercised options and sold US$479k worth of stock

Executive VP notifies of intention to sell stock

Exelixis, Inc Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult

Independent Director recently sold US$907k worth of stock

Consensus EPS estimates increase by 37%

Insider notifies of intention to sell stock

Exelixis Comes Up Aces

Exelixis, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $500 million worth of its shares.

Exelixis, Inc. Announces U.S. Food and Drug Administration Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors

Exelixis, Inc. to Report Q2, 2024 Results on Aug 06, 2024

If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

Independent Director recently sold US$576k worth of stock

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

Independent Director notifies of intention to sell stock

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Exelixis, Inc., Annual General Meeting, May 30, 2024

Exelixis, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Independent Director notifies of intention to sell stock

Executive Vice President of Commercial recently sold US$1.0m worth of stock

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Executive Vice President of Commercial notifies of intention to sell stock

Full year 2023 earnings: EPS exceeds analyst expectations

Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024

Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Executive VP notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Exelixis Announces Initiation of the Stellar-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

Exelixis, Inc. Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.23 in 3Q 2022)

Consensus EPS estimates fall by 10%

Exelixis, Inc. Announces Detailed Results from Phase 3 Cabinet Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

Exelixis, Inc. to Report Q3, 2023 Results on Nov 01, 2023

CEO, President & Director exercised options and sold US$2.1m worth of stock

Exelixis, Inc. Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

Exelixis, Inc. Announces Vicki L. Goodman Concludes Her Service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer